{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:34:13Z","timestamp":1789011253695,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.canlet.2017.09.034","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T12:47:08Z","timestamp":1506689228000},"page":"180-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pharmacological evidence for the bone-autonomous contribution of the NF\u03baB\/\u03b2-catenin axis to breast cancer related osteolysis"],"prefix":"10.1016","volume":"410","author":[{"given":"Silvia","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-700X","authenticated-orcid":false,"given":"John G.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mollat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-5306","authenticated-orcid":false,"given":"Aymen I.","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2017.09.034_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2017.09.034_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canlet.2017.09.034_bib3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2017.09.034_bib4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10555-006-9023-1","article-title":"Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases","volume":"25","author":"Siclari","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2017.09.034_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2017.09.034_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/15216540500137669","article-title":"RANKing intracellular signaling in osteoclasts","volume":"57","author":"Feng","year":"2005","journal-title":"IUBMB.Life"},{"key":"10.1016\/j.canlet.2017.09.034_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.emboj.7600564","article-title":"RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis","volume":"24","author":"Gohda","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2017.09.034_bib8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1128\/MCB.22.4.992-1000.2002","article-title":"Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6","volume":"22","author":"Mizukami","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2017.09.034_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1242\/jcs.115.4.679","article-title":"All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction","volume":"115","author":"Chung","year":"2002","journal-title":"J.Cell Sci."},{"key":"10.1016\/j.canlet.2017.09.034_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2443.2005.00852.x","article-title":"TAK1-binding protein 2 facilitates ubiquitination of TRAF6 and assembly of TRAF6 with IKK in the IL-1 signaling pathway","volume":"10","author":"Kishida","year":"2005","journal-title":"Genes Cells."},{"key":"10.1016\/j.canlet.2017.09.034_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1101\/gad.13.8.1015","article-title":"TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling","volume":"13","author":"Lomaga","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2017.09.034_bib12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bbrc.2007.06.017","article-title":"TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation","volume":"359","author":"Lamothe","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2017.09.034_bib13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/jbmr.4","article-title":"IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis","volume":"25","author":"Otero","year":"2010","journal-title":"J.Bone Miner.Res."},{"key":"10.1016\/j.canlet.2017.09.034_bib14","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.20042081","article-title":"I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss","volume":"201","author":"Ruocco","year":"2005","journal-title":"J.\u00a0Exp.Med."},{"key":"10.1016\/j.canlet.2017.09.034_bib15","doi-asserted-by":"crossref","first-page":"54841","DOI":"10.1074\/jbc.M406392200","article-title":"Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha","volume":"279","author":"Chaisson","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.09.034_bib16","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1096\/fj.10-164095","article-title":"Small molecule inhibitors of I{kappa}B kinase signaling inhibit osteoclast formation in\u00a0vitro and prevent ovariectomy-induced bone loss in\u00a0vivo","volume":"24","author":"Idris","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2017.09.034_bib17","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.11131","article-title":"A\u00a0highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice","volume":"48","author":"McIntyre","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.canlet.2017.09.034_bib18","doi-asserted-by":"crossref","first-page":"37219","DOI":"10.1074\/jbc.C400258200","article-title":"The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis","volume":"279","author":"Dai","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.09.034_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nm1054","article-title":"Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in\u00a0vivo","volume":"10","author":"Jimi","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2017.09.034_bib20","article-title":"Amlexanox suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2017.09.034_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10585-004-1867-6","article-title":"Metastatic breast cancer cells suppress osteoblast adhesion and differentiation","volume":"21","author":"Mercer","year":"2004","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2017.09.034_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1749-6632.2009.05315.x","article-title":"Functions of nuclear factor kappaB in bone","volume":"1192","author":"Boyce","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2017.09.034_bib23","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling","volume":"116","author":"Krishnan","year":"2006","journal-title":"J.\u00a0Clin.Invest"},{"key":"10.1016\/j.canlet.2017.09.034_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm.1954","article-title":"Inhibition of osteoblastic bone formation by nuclear factor-kappaB","volume":"15","author":"Chang","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2017.09.034_bib25","doi-asserted-by":"crossref","first-page":"9469","DOI":"10.1073\/pnas.1300532110","article-title":"NF-kappaB inhibits osteogenic differentiation of mesenchymal stem cells by promoting beta-catenin degradation","volume":"110","author":"Chang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2017.09.034_bib26","doi-asserted-by":"crossref","first-page":"18009","DOI":"10.1074\/jbc.M115.646208","article-title":"Increased NF-kappaB activity and decreased Wnt\/beta-catenin signaling mediate reduced osteoblast differentiation and function in DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) mice","volume":"290","author":"Le Henaff","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.09.034_bib27","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1186\/bcr3048","article-title":"Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2\/CBFbeta-dependent expression of the Wnt antagonist, sclerostin","volume":"13","author":"Mendoza-Villanueva","year":"2011","journal-title":"Breast Cancer Res. BCR"},{"key":"10.1016\/j.canlet.2017.09.034_bib28","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/MCB.05980-11","article-title":"Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin","volume":"31","author":"Wei","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2017.09.034_bib29","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.1102836","article-title":"TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis","volume":"188","author":"Otero","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2017.09.034_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1083\/jcb.201207142","article-title":"Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin","volume":"200","author":"Albers","year":"2013","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.canlet.2017.09.034_bib31","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1172\/JCI90527","article-title":"RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146","volume":"127","author":"Matsumoto","year":"2017","journal-title":"J.\u00a0Clin. Investigation"},{"key":"10.1016\/j.canlet.2017.09.034_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1615\/ForumImmunDisTher.v1.i3.10","article-title":"Cross-regulation between Wnt and NF-kappaB signaling pathways","volume":"1","author":"Du","year":"2010","journal-title":"For Immunopathol Dis Ther."},{"key":"10.1016\/j.canlet.2017.09.034_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm1519","article-title":"NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF","volume":"13","author":"Park","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2017.09.034_bib34","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/1535-7163.MCT-09-0133","article-title":"Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in\u00a0vitro and prevent osteolytic bone metastasis in\u00a0vivo","volume":"8","author":"Idris","year":"2009","journal-title":"Mol. cancer Ther."},{"key":"10.1016\/j.canlet.2017.09.034_bib35","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1074-5521(01)00049-7","article-title":"The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase","volume":"8","author":"Kwok","year":"2001","journal-title":"Chem. Biol."},{"key":"10.1016\/j.canlet.2017.09.034_bib36","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.4049\/jimmunol.163.10.5617","article-title":"The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex","volume":"163","author":"Hehner","year":"1999","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2017.09.034_bib37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2010.06.002","article-title":"What made sesquiterpene lactones reach cancer clinical trials?","volume":"15","author":"Ghantous","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2017.09.034_bib38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bone.2003.07.012","article-title":"In\u00a0vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells","volume":"34","author":"Rucci","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.canlet.2017.09.034_bib39","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/jbmr.1847","article-title":"Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis","volume":"28","author":"Logan","year":"2013","journal-title":"J.\u00a0bone mineral Res. official J. Am. Soc. Bone Mineral Res."},{"key":"10.1016\/j.canlet.2017.09.034_bib40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1541-7786.MCR-07-0119","article-title":"Osteoactivin promotes breast cancer metastasis to bone","volume":"5","author":"Rose","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2017.09.034_bib41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/bonekey.2014.59","article-title":"Quantitative analysis of bone and soft tissue by micro-computed tomography: applications to ex\u00a0vivo and in\u00a0vivo studies","volume":"3","author":"Campbell","year":"2014","journal-title":"BoneKEy Rep."},{"issue":"36","key":"10.1016\/j.canlet.2017.09.034_bib42","doi-asserted-by":"crossref","first-page":"22049","DOI":"10.1074\/jbc.M115.649608","article-title":"Bone cell-autonomous contribution of type 2 cannabinoid receptor to breast cancer induced osteolysis","volume":"290","author":"Sophocleous","year":"2015","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2017.09.034_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bonekey.2014.80","article-title":"Generation of rodent and human osteoblasts","volume":"3","author":"Taylor","year":"2014","journal-title":"BoneKEy Rep."},{"key":"10.1016\/j.canlet.2017.09.034_bib44","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2006-10-050807","article-title":"Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation","volume":"109","author":"Sethi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.09.034_bib45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.canlet.2017.09.034_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jlb.61.4.381","article-title":"Osteoclasts, macrophages, and the\u00a0molecular mechanisms of bone resorption","volume":"61","author":"Teitelbaum","year":"1997","journal-title":"J.\u00a0Leukoc.Biol."},{"key":"10.1016\/j.canlet.2017.09.034_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.5483\/BMBRep.2014.47.8.206","article-title":"Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis","volume":"47","author":"Kim","year":"2014","journal-title":"BMB Rep."},{"key":"10.1016\/j.canlet.2017.09.034_bib48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/360741a0","article-title":"Bone and haematopoietic defects in mice lacking c-fos","volume":"360","author":"Wang","year":"1992","journal-title":"Nature"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517305876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517305876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T15:22:38Z","timestamp":1693063358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383517305876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":48,"alternative-id":["S0304383517305876"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2017.09.034","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological evidence for the bone-autonomous contribution of the NF\u03baB\/\u03b2-catenin axis to breast cancer related osteolysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2017.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}